Rational design of new multitarget histamine H3 receptor ligands as potential candidates for treatment of Alzheimer's disease.

Abstract

Design and development of multitarget-directed ligands (MTDLs) has become a very important approach in the search of new therapies for Alzheimer's disease (AD). In our present research, a number of xanthone derivatives were first designed using a pharmacophore model for histamine H3 receptor (H3R) antagonists/inverse agonists, and virtual docking was then performed for the enzyme acetylcholinesterase. Next, 23 compounds were synthesised and evaluated in vitro for human H3R (hH3R) affinity and inhibitory activity on cholinesterases. Most of the target compounds showed hH3R affinities in nanomolar range and exhibited cholinesterase inhibitory activity with IC50 values in submicromolar range. Furthermore, the inhibitory effects of monoamine oxidases (MAO) A and B were investigated. The results showed low micromolar and selective human MAO B (hMAO B) inhibition. Two azepane derivatives, namely 23 (2-(5-(azepan-1-yl)pentyloxy)-9H-xanthen-9-one) and 25 (2-(5-(azepan-1-yl)pentyloxy)-7-chloro-9H-xanthen-9-one), were especially very promising and showed high affinity for hH3R (Ki = 170 nM and 100 nM respectively) and high inhibitory activity for acetylcholinesterase (IC50 = 180 nM and 136 nM respectively). Moreover, these compounds showed moderate inhibitory activity for butyrylcholinesterase (IC50 = 880 nM and 394 nM respectively) and hMAO B (IC50 = 775 nM and 897 nM respectively). Furthermore, molecular docking studies were performed for hH3R, human cholinesterases and hMAO B to describe the mode of interactions with these biological targets. Next, the two most promising compounds 23 and 25 were selected for in vivo studies. The results showed significant memory-enhancing effect of compound 23 in dizocilpine-induced amnesia in rats in two tests: step-through inhibitory avoidance paradigm (SIAP) and transfer latency paradigm time (TLPT). In addition, favourable analgesic effects of compound 23 were observed in neuropathic pain models. Therefore, compound 23 is a particularly promising structure for further design of new MTDLs for AD.

• Authors: Dorota Łażewska, Marek Bajda, Maria Kaleta, Paula Zaręba, Agata Doroz-Płonka, Agata Siwek, Alaa Alachkar, Szczepan Mogilski, Ali Saad, Kamil Kuder, Agnieszka Olejarz-Maciej, Justyna Godyń, Dorota Stary, Sylwia Sudoł, Małgorzata Więcek, Gniewomir Latacz, Maria Walczak, Jadwiga Handzlik, Bassem Sadek, Barbara Malawska, Katarzyna Kieć-Kononowicz
• Journal: European journal of medicinal chemistry (Eur J Med Chem) Vol. 207 Pg. 112743 (Dec 01 2020) ISSN: 1768-3254 [Electronic] France
• PMID: 32882609 (Publication Type: Journal Article)
• Copyright: Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Chemical References

• Cholinesterase Inhibitors
• Ligands
• Monoamine Oxidase Inhibitors
• Receptors, Histamine H3

Topics

• Alzheimer Disease (drug therapy, metabolism)
• Animals
• Cholinesterase Inhibitors (chemistry, metabolism, pharmacology, therapeutic use)
• Drug Design
• Humans
• Ligands
• Male
• Mice
• Molecular Docking Simulation
• Molecular Targeted Therapy
• Monoamine Oxidase Inhibitors (chemistry, metabolism, pharmacology, therapeutic use)
• Protein Conformation
• Receptors, Histamine H3 (chemistry, metabolism)